Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10934170 | 0.98 | GAA (0.70) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL14543348 | 0.94 | GAA (0.73) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL11293119 | 0.87 | GAA (0.85) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL2666138 | 0.84 | GAA (1.00) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL1567500 | 0.83 | CES2 (0.53) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL14134416 | 0.82 | GAA (0.96) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL10280045 | 0.81 | GAA (0.74) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL30250490 | 0.80 | ALDH1A1 (0.55) | GAAALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL642316 | 0.79 | GAA (0.72) | GAAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL3700972 | 0.79 | GAA (0.72) | GAAALDH1A1SMN1; SMN2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417385-A1 | COMPOUND AND USE THEREOF FOR TREATING EMOTIONAL BEHAVIORAL DISORDERS | NEUROVENTI INC. (KR) | 2024-12-19 | — | — | US | claimed |
| EP-4400494-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATING EMOTIONAL BEHAVIORAL DISORDERS | Neuroventi Inc. (KR) | 2024-07-17 | — | — | EP | claimed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | claimed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| EP-1071680-B1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1071680-A4 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2003-03-05 | — | — | EP | claimed |
| US-6194448-B1 | ANTIINFLAMMATORY AGENTS; ASTHMA; RHEUMATIC DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION | 2001-02-27 | — | — | US | claimed |
| EP-1071680-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-31 | — | — | EP | claimed |
| WO-1999052898-A1 | N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-21 | — | — | WO | claimed |
| EP-0083315-B1 | PYRIDYL-N-OXIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1987-07-29 | — | — | EP | claimed |
| US-4497808-A | N-Oxide compounds useful in the treatment of cardiovascular ailments | CIBA-GEIGY CORPORATION (US) | 1985-02-05 | — | — | US | claimed |
| EP-0111455-A2 | Unsaturated lactones | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | claimed |
| EP-0083315-A2 | Pyridyl-N-oxides, processes for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1983-07-06 | — | — | EP | claimed |
| CN-117820287-B | Magnolol derivative, and preparation method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117800942-B | Thiophene piperazine amide derivative, composition and application thereof | 徐州医科大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-0111453-A1 | Amide derivatives | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0111455-A2 | Unsaturated lactones | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| EP-0083315-A2 | Pyridyl-N-oxides, processes for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417385-A1 | COMPOUND AND USE THEREOF FOR TREATING EMOTIONAL BEHAVIORAL DISORDERS | ADCYAP1R1, GRIA1, GRIA4 | GAA 19/4885ALDH1A1 751/4885SMN1; SMN2 3284/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | GAA 1526/4885ALDH1A1 2206/4885SMN1; SMN2 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.